Biocartis Group N.V. (BIOGF) Research

Biocartis Group N.V. is a molecular diagnostics firm dedicated to advancing clinical practice through innovative diagnostic solutions. These offerings aim to benefit patients, clinicians, healthcare payers, and the wider healthcare industry, with a particular emphasis on the field of oncology. Central to their product portfolio is the proprietary Idylla platform, a real-time polymerase chain reaction (PCR) system. This cutting-edge technology delivers vital molecular information, which is instrumental in both selecting appropriate treatments and continuously monitoring their effectiveness. The company provides a diverse array of Idylla tests, including mutation analyses for oncology biomarkers such as BRAF, KRAS, MSI, EGFR, and NRAS-BRAF. Beyond cancer diagnostics, they also offer panels for infectious diseases, specifically Idylla SARS-CoV-2/Flu/RSV and standalone SARS-CoV-2 tests. Additionally, their SeptiCyte RAPID test offers quick assessment of host response. For research purposes, Biocartis supplies various assays for detecting mutations, including those for MSI, KRAS, BRAF, ctEGFR, NRAS-BRAF-EGFR S492R, ctKRAS, EGFR, GeneFusion, ctBRAF, and ctNRAS-BRAF-EGFR S492R. Biocartis actively engages in strategic collaborations. They have partnered with Amgen to evaluate the Idylla RAS testing capabilities, aiming for rapid, decentralized diagnostics and faster access to crucial RAS biomarker data via the Idylla platform. Another collaboration with Bristol-Myers Squibb Company focuses on the regulatory approval and application of the Idylla MSI test in conjunction with immuno-oncology therapies. Furthermore, Biocartis holds a licensing, development, and commercialization agreement with GeneproDx for integrating the novel ThyroidPrint genomic test onto the Idylla platform. Founded in 2007, Biocartis Group N.V. operates from its headquarters located in Mechelen, Belgium.

Open Biocartis Group N.V. (BIOGF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.